0001439222-24-000004.txt : 20240109 0001439222-24-000004.hdr.sgml : 20240109 20240109162209 ACCESSION NUMBER: 0001439222-24-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240105 FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gheuens Sarah CENTRAL INDEX KEY: 0001881190 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 24523520 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wk-form4_1704835314.xml FORM 4 X0508 4 2024-01-05 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001881190 Gheuens Sarah 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer 1 Common stock 2024-01-05 4 M 0 5000 0 A 29658 D Common stock 2024-01-09 4 S 0 1789 22.99 D 27869 D Performance share units 2024-01-05 4 M 0 5000 0 D Common stock 5000 0 D Includes 499 shares purchased through the Company's employee stock purchase plan. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 1, 2021. Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The PSUs were granted on September 1, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. /s/ William Cook, as attorney-in-fact for Sarah Gheuens 2024-01-09